<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7460442\results\search\drug\results.xml">
  <result pre="in progress has been delineated. COVID-19 cytokine storm clinical features" exact="dexamethasone" post="epidemiology life cycle pathogenesis RT-PCR remdesivir SARS-CoV-2 therapeutics vaccines"/>
  <result pre="to manage the fever is acetaminophen, while expectorants such as" exact="guaifenesin" post="are used for non-productive cough [90]. Patients with SARS,"/>
  <result pre="a nucleotide analog and is metabolized in the cell to" exact="adenosine" post="triphosphate analog, which inhibits the viral RNA polymerases. Remdesivir"/>
  <result pre="edition of treatment guidelines for combating COVID-19. Later, arbidol and" exact="chloroquine" post="phosphate have also been added in the 6th edition,"/>
  <result pre="beyond standard care [108]. On the basis of the guidelines," exact="ritonavir" post="is used as a booster to enhance the efficacy"/>
  <result pre="possibly useful and can be employed [59]. A glucocorticoids-based drug" exact="dexamethasone" post="may be employed against COVID-19. Dexamethasone is a synthetic"/>
  <result pre="COVID-19 patients [112]. A recent controlled open-label, randomized trial of" exact="dexamethasone" post="in hospitalized patients, concluded that the use of dexamethasone"/>
  <result pre="of dexamethasone in hospitalized patients, concluded that the use of" exact="dexamethasone" post="with the aid of mechanical ventilation or oxygen alone"/>
  <result pre="dose of 6 mg once daily for 10 days. However," exact="dexamethasone" post="was not effective in those patients who were not"/>
  <result pre="been updated to recommend the use of glucocorticoids such as" exact="dexamethasone" post="in hospitalized patients with COVID-19 [114,115]. As discussed earlier,"/>
  <result pre="the infection and are supposed to be less effective [90]." exact="Chloroquine" post="and its derivative hydroxychloroquine are considered to be effective"/>
  <result pre="supposed to be less effective [90]. Chloroquine and its derivative" exact="hydroxychloroquine" post="are considered to be effective against COVID-19 and are"/>
  <result pre="of treatment [116]. An open-label, non-randomized clinical trial showed that" exact="hydroxychloroquine" post="(600 mg/day) treatment is magnificently related to a decreased"/>
  <result pre="viral replication in patients, and its effectiveness is reinforced by" exact="azithromycin" post="(500 mg/day) [116]. Hydroxychloroquine showed superior sensitivity over chloroquine"/>
  <result pre="and its effectiveness is reinforced by azithromycin (500 mg/day) [116]." exact="Hydroxychloroquine" post="showed superior sensitivity over chloroquine against COVID-19 [117]. Contrary"/>
  <result pre="by azithromycin (500 mg/day) [116]. Hydroxychloroquine showed superior sensitivity over" exact="chloroquine" post="against COVID-19 [117]. Contrary to the previous results, at"/>
  <result pre="open-label, randomized controlled clinical trial showed that the use of" exact="hydroxychloroquine" post="alone or with azithromycin did not improve the clinical"/>
  <result pre="trial showed that the use of hydroxychloroquine alone or with" exact="azithromycin" post="did not improve the clinical status of hospitalized patients"/>
  <result pre="can be controlled with the use of protease inhibitors, including" exact="camostat" post="and nafamostat, which target TMPRSS2, and thereby inhibit the"/>
  <result pre="the clinical results of the patients. These broad-spectrum antibiotics, including" exact="azithromycin" post="and fluoroquinolones, can be given as empirical therapy to"/>
  <result pre="bacteria are cleared from the body. The combination therapy of" exact="azithromycin" post="with hydroxychloroquine showed significant activity against COVID-19 infection [124]."/>
  <result pre="cleared from the body. The combination therapy of azithromycin with" exact="hydroxychloroquine" post="showed significant activity against COVID-19 infection [124]. Table 5"/>
  <result pre="potential therapeutics against COVID-19. Some researchers recommend the use of" exact="vitamin C" post="supplements that may help to treat the clinical symptoms"/>
  <result pre="pneumonia; however, this requires more clinical evaluation [131]. Supplements of" exact="vitamin D3" post="can also be useful for combating the infection. While"/>
  <result pre="have been used for antiviral or anti-parasite ones such as" exact="chloroquine" post="phosphate and lopinavir/ritonavir. Among them, remdesivir has been approved"/>
  <result pre="89.SinghalT.A review of coronavirus disease-2019 (COVID-19)Indian J. Pediatr.20208728128610.1007/s12098-020-03263-632166607 90.WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  <result pre="Treatment GuidelinesAvailable online: https://www.covid19treatmentguidelines.nih.gov/dexamethasone/(accessed on 30 July 2020) 116.GautretP.LagierJ.-C.ParolaP.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.DupontH.T.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: Results of an open-label"/>
  <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
  <result pre="coronavirus 2 (SARS-CoV-2)Clin. Infect. Dis.2020210.1093/cid/ciaa23732150618 118.CavalcantiA.B.ZampieriF.G.RosaR.G.AzevedoL.C.VeigaV.C.AvezumA.DamianiL.P.MarcadentiA.Kawano-DouradoL.LisboaT.et al.Hydroxychloroquine with or without" exact="Azithromycin" post="in Mild-to-Moderate Covid-19N. Engl. J. Med.202010.1056/NEJMoa2019014 119.KlokF.KruipM.Van der MeerN.ArbousM.GommersD.KantK.KapteinF.Van"/>
  <result pre="rapid antiviral clearance or clinical benefit with the combination of" exact="hydroxychloroquine" post="and azithromycin in patients with severe COVID-19 infectionMed. Mal."/>
  <result pre="clearance or clinical benefit with the combination of hydroxychloroquine and" exact="azithromycin" post="in patients with severe COVID-19 infectionMed. Mal. Infect.2020300853008810.1016/j.medmal.2020.03.006 125.JinY.YangH.JiW.WuW.ChenS.ZhangW.DuanG.Virology,"/>
  <result pre="the dysfunctional immune response, cells may undergo pyroptosis and release" exact="adenosine" post="triphosphate (ATP), nucleic acids, and ASC oligomer. These impaired-associated"/>
  <result pre="day. Drug Regimen Dosage Route of Administration Length of Therapy" exact="Ribavirin" post="500 mg, t.i.d, combination therapy with lopinavir/ritonavir IV infusion"/>
  <result pre="mg, t.i.d, combination therapy with lopinavir/ritonavir IV infusion â‰¤10 days" exact="Chloroquine" post="phosphate 500 mg one time, b.i.d Orally â‰¤10 days"/>
  <result pre="provides protective antibodies against SARS-CoV-2 Clinical trials have been conducted" exact="Chloroquine" post="Hydroxychloroquine Anti-malaria Inhibition of endosomal acidified fusion and also"/>
  <result pre="protective antibodies against SARS-CoV-2 Clinical trials have been conducted Chloroquine" exact="Hydroxychloroquine" post="Anti-malaria Inhibition of endosomal acidified fusion and also have"/>
  <result pre="antiviral property, as it also enhances the therapeutic activity of" exact="hydroxychloroquine" post="Clinical trials have been conducted Enoxaparin Low molecular weight"/>
 </snippets>
</snippetsTree>
